ライフサイエンスコーパス: JEV

1 JEV or WNV was reliably identified as the currently infe

2 JEV provides a paradigm for other flaviviruses, includin

3 Analysis of all 290 JEV isolates for which sequence data are available showe

4 le of T cell responses in protection against JEV, we conducted the first full-breadth analysis of the

5 ta suggest cross-protection between DENV and JEV.

6 urther application of the assays to WNV- and JEV-infected serum panels showed similar results.

7 The live-attenuated JEV SA14-14-2 vaccine has been vital for controlling the

8 ated JE-VAX and then boosted with attenuated JEV SA14-14-2.

9 The authentic JEV SA14-14-2 (E) protein, with amino acid substitutions

10 ntrolling the incidence of disease caused by JEV, particularly in rural areas of Asia where it is end

11 inflammatory cytokines/chemokines induced by JEV infection that inhibit the expression of TJ proteins

12 serum specimens from patients with confirmed JEV and WNV infections and compared the results with prM

13 ed recombinant JEV (rJEV) strains containing JEV SA14-14-2 vaccine-specific mutations that are locate

14 specimens from patients with confirmed DENV, JEV, and WNV infections, along with naive sera, were sub

15 Phylogenetic studies divided JEV into five geographically and epidemiologically disti

16 ed with displacement of GIII as the dominant JEV genotype throughout Asia in the 1990s.

17 when applied in areas that were endemic for JEV.

18 specificity of serodiagnosis, especially for JEV infection, was increased to 90% when applied in area

19 at least 3.5 PFU/ml for YFV, 2.0 PFU/ml for JEV, 10.0 PFU/ml for WNV, and 10.0 PFU/ml for SLEV.

20 amma (IFN-gamma) responses to JEV in healthy JEV-exposed donors were mostly CD8(+) and targeted nonst

21 standing the mechanisms of BBB disruption in JEV infection is important.

22 rated the enhancement of BBB permeability in JEV-infected mice, suggesting that IFN-gamma could be a

23 rated the enhancement of BBB permeability in JEV-infected mice.

24 Here, using a mouse model of intravenous JEV infection, we show that virus titers increased expon

25 mouse of MAb B2 1 day after otherwise lethal JEV infection protected 50% of mice and significantly pr

26 d one or two doses of DNA vaccine maintained JEV-specific antibodies 18 months after initial immuniza

27 rus dengue virus (DENV) cocirculates in many JEV-endemic areas, and clinical data suggest cross-prote

28 t al. report the cryo-EM structure of mature JEV at near-atomic resolution and identify structural el

29 Sera from JENVAC subjects neutralized JEV genotypes I, II, III, and IV equally well.

30 Furthermore, it is not JEV infection per se, but the inflammatory cytokines/che

31 GIII has been the source of numerous JEV epidemics throughout history and was the most freque

32 dult mice that had received a single dose of JEV DNA vaccine when 3 days of age were completely prote

33 donesia-Malaysia region has all genotypes of JEV circulating, whereas only more recent genotypes circ

34 cs, we comprehensively defined the impact of JEV SA14-14-2 mutations on attenuation of virulence and

35 ses linked to different clinical outcomes of JEV infection, associated with distinct targeting and br

36 nstration of antibody-mediated protection of JEV infection in vivo is provided using the mouse enceph

37 ly infecting flavivirus by a higher ratio of JEV-to-WNV P/N values or vice versa.

38 and reliable result for the serodiagnosis of JEV and WNV infections without the need for PRNT.

39 izing activities against a broad spectrum of JEV genotype strains.

40 this study, we demonstrate that the TMDs of JEV NS2B participate in both viral RNA replication and v

41 ial therapeutic avenues for the treatment of JEV infection.

42 f the core protein unlike that seen in other JEV strains.

43 Pathologically, JEV infection causes an acute encephalopathy accompanied

44 were completely protected from a 50, 000-PFU JEV intraperitoneal challenge.

45 hat a recombinant plasmid DNA which produced JEV EPs in vitro is an effective vaccine.

46 ond-generation, live-attenuated, recombinant JEV vaccine candidates.

47 Here, we generated recombinant JEV (rJEV) strains containing JEV SA14-14-2 vaccine-spec

48 h this plasmid vector (JE-4B clone) secreted JEV-specific extracellular particles (EPs) into the cult

49 While monomeric in solution, JEV E assembles as an antiparallel dimer in the crystal

50 ver, brain extracts derived from symptomatic JEV-infected mice, but not from mock-infected mice, indu

51 Our data demonstrate that JEV gains entry into the CNS prior to BBB disruption.

52 Taken together, our data suggest that JEV enters the CNS, propagates in neurons, and induces t

53 These results suggest that JEV originated from its ancestral virus in the Indonesia

54 The JEV envelope protein (E) facilitates cellular attachment

55 Using the recombination trap and the JEV system, we detected two aberrant recombination event

56 sters and not mice were also detected in the JEV SA-14-14-2 vaccine.

57 ammaretrovirus sequences was detected in the JEV vaccine using PCR.

58 he 2.1-A resolution crystal structure of the JEV E ectodomain refolded from bacterial inclusion bodie

59 Attenuation depends on the presence of the JEV SA14-14-2 E protein, as shown by the high neurovirul

60 introduced from PCR-amplified regions of the JEV SA14-14-2 genome.

61 E of YFV 17D are replaced with those of the JEV SA14-14-2 vaccine strain is under evaluation as a ca

62 ts are consistent with the production of the JEV vaccine in Syrian hamster cells.

63 on, uniquely conserved histidines within the JEV serocomplex suggest that pH-mediated structural tran

64 ever, the majority of individuals exposed to JEV only develop mild symptoms associated with long-last

65 vo interferon-gamma (IFN-gamma) responses to JEV in healthy JEV-exposed donors were mostly CD8(+) and

66 veloped >25 years ago by passaging wild-type JEV strain SA14 in tissue cultures and rodents, with int

67 Despite the existence of effective vaccines, JEV is responsible for an estimated 68,000 human cases a

68 itoneal challenge with 5,000 PFU of virulent JEV strain SA14.

69 ines, including Japanese encephalitis virus (JEV) (SA-14-14-2), varicella (Varivax), measles, mumps,

70 irus (YFV), and Japanese encephalitis virus (JEV) and by comparing the resultant chimeric viruses gen

71 gnosis of acute Japanese encephalitis virus (JEV) and West Nile virus (WNV) infections is the prememb

72 ur genotypes of Japanese encephalitis virus (JEV) are presently recognized (representatives of genoty

73 Nile virus, and Japanese encephalitis virus (JEV) are widely used as serodiagnostic tests for presump

74 Using Japanese encephalitis virus (JEV) as a model, we performed a systematic mutagenesis a

75 ver virus (YFV)/Japanese encephalitis virus (JEV) chimera in which the structural proteins prM and E

76 otype I (GI) of Japanese encephalitis virus (JEV) has displaced genotype III (GIII) as the dominant v

77 ic flaviviruses.Japanese encephalitis virus (JEV) is a Flavivirus responsible for thousands of deaths

78 Japanese encephalitis virus (JEV) is the leading global cause of viral encephalitis.

79 tors containing Japanese encephalitis virus (JEV) premembrane (prM) and envelope (E) genes were const

80 live-attenuated Japanese encephalitis virus (JEV) SA14-14-2 vaccine are attributed to mutations that

81 irus (WNV), and Japanese encephalitis virus (JEV) that could complement each other in trans and thus

82 Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, represents the most s

83 Japanese encephalitis virus (JEV), although confined to Asia, causes about 35000-5000

84 o virus (KOUV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV), and Bagaza vi

85 DENV, WNV, and Japanese encephalitis virus (JEV), using a high-content immunofluorescence screen.

86 We diagnosed Japanese encephalitis virus (JEV), using antibody detection, culture of serum and CSF

87 irus (WNV), and Japanese encephalitis virus (JEV), were constructed.

88 er virus (YFV), Japanese encephalitis virus (JEV), West Nile virus (WNV), St.

89 Japanese encephalitis virus (JEV)-specific Fab antibodies were recovered by repertoir

90 sease caused by Japanese encephalitis virus (JEV).

91 irus (HCV), and Japanese encephalitis virus (JEV).

92 eveloped using an Indian strain of JE virus (JEV).

93 Japanese encephalitis (JE) virus (JEV) is an important cause of encephalitis in children o

94 increased to 90% when applied in areas where JEV cocirculates with WNV, or to 100% when applied in ar

95 V/JEV Nakayama chimera derived from the wild JEV Nakayama strain.

96 CNS infections, 144 (26%) were infected with JEV (134 children and 10 adults).

97 studies revealed that direct infection with JEV could not induce changes in the permeability of brai

98 fluorogenic probes (probes specific for YFV, JEV, WNV, and SLEV) and four previously published probes

99 the high neurovirulence of an analogous YFV/JEV Nakayama chimera derived from the wild JEV Nakayama

100 The chimera (YFV/JEV SA14-14-2, or ChimeriVax-JE) is less neurovirulent t

101 d in attenuation, a series of intratypic YFV/JEV chimeras containing either single or multiple amino

102 the E proteins of ChimeriVax-JE and the YFV/JEV Nakayama virus, four of which are predicted to be ne

103 estore the neurovirulence typical of the YFV/JEV Nakayama virus.